1. The Impact of Gastric Acid Suppression on the Developing Intestinal Microbiome of A Child

    Submitted by centretek on Sat, 10/15/2022 - 10:29
    Summary
    Medications to suppress gastric acid are often used in children for conditions such as gastroesophageal reflux disease or GERD. We are learning more about potential side effects of these medications including Clostridium difficile infection and small bowel bacterial overgrowth which may be due to the underlying effect of these medications on the intestinal microbiome. The microbiome of a child develops in the first few years of life and so young children may be particularly vulnerable to these medications. We are examining the gut microbiome of young children before and after using these medications. This will give insight into possible mechanisms for reported side effects and may give data to guide appropriate use of these commonly used medications in childhood.
  2. Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) That Progressed After Platinum Therapy and

    Submitted by centretek on Sat, 10/15/2022 - 10:29
  3. Merck 689: A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

    Submitted by centretek on Sat, 10/15/2022 - 10:29